Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis
This cost-effectiveness analysis based on the RATIONALE-312 trial demonstrates that tislelizumab plus platinum and etoposide is a cost-effective treatment option for ES-SCLC compared to the standard chemotherapy from the Chinese medical system perspective.
Authors
- Huide Zhu
- Zhiwei Zheng (ORCID: https://orcid.org/0000-0002-7815-3221)
- Ling Fang (ORCID: https://orcid.org/0000-0002-3070-1022)
Institutions
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1371/journal.pone.0320189
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09